We are live on ! Find out more
WVP

Worth Venture Partners Portfolio holdings

AUM $31.6M
1-Year Est. Return 28.5%
This Fund
S&P 500
This Quarter Est. Return
-6.1%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
–
AUM
$13.5M
AUM Growth
-$1.55M
Cap. Flow
+$17.1M
Cap. Flow %
126.71%
Top 10 Hldgs %
54.64%
Holding
84
New
22
Increased
18
Reduced
8
Closed
28

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$801K
2
WEAV icon
Weave Communications
WEAV
+$715K
3
VKTX icon
Viking Therapeutics
VKTX
+$662K
4
SRG
Seritage Growth Properties
SRG
+$385K
5
ML
MoneyLion Inc.
ML
+$305K

Top Sells

Rank Stock Value
1
AIP icon
Arteris
AIP
+$1.01M
2
IHI icon
iShares US Medical Devices ETF
IHI
+$908K
3
INSM icon
Insmed
INSM
+$597K
4
APLS
Apellis Pharmaceuticals
APLS
+$453K
5
NVO
Novo Nordisk
NVO
+$385K

Sector Composition

Rank Sector Weight
1 Healthcare 30.58%
2 Real Estate 24.99%
3 Technology 20.99%
4 Communication Services 7.7%
5 Financials 5.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTV
51
DELISTED
Innovid Corp.
CTV
$27.5K 0.2%
14,872
-29,953
-67% -$64.2K
XLV icon
52
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$26.5K 0.2%
+28,200
New +$4.05M
PFE icon
53
CALL
Pfizer
PFE
$143B
$17.1K 0.13%
+28,900
New +$796K
PFE icon
54
PUT
Pfizer
PFE
$143B
$5.29K 0.04%
+43,200
New +$1.19M
CMPS
55
CALL
Compass Pathways
CMPS
$1.53B
$2.09K 0.02%
16,700
– –
INSM icon
56
PUT
Insmed
INSM
$21.4B
$358 ﹤0.01%
14,300
-1,100
-7% -$42.7K
ACAD icon
57
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-92,400
Closed -$7.84K
AIP icon
58
Arteris
AIP
$1.38B
– –
-138,591
Closed -$1.01M
AKBA icon
59
CALL
Akebia Therapeutics
AKBA
$354M
– –
-23,300
Closed -$50.1K
AKBA icon
60
PUT
Akebia Therapeutics
AKBA
$354M
– –
-120,000
Closed -$9K
AMLX icon
61
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-32,200
Closed -$805
APLS
62
DELISTED
Apellis Pharmaceuticals
APLS
– –
-7,700
Closed -$453K
BCRX icon
63
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-39,000
Closed -$198K
BCRX icon
64
PUT
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-39,000
Closed -$1.95K
EGAN icon
65
eGain
EGAN
$187M
– –
-57,412
Closed -$370K
FENC icon
66
Fennec Pharmaceuticals
FENC
$332M
– –
-10,327
Closed -$115K
GEO icon
67
The GEO Group
GEO
$4.13B
– –
-10,590
Closed -$150K
IHI icon
68
iShares US Medical Devices ETF
IHI
$3.13B
– –
-15,500
Closed -$908K
ILCV icon
69
PUT
iShares Morningstar Value ETF
ILCV
$1.32B
– –
-15,500
Closed -$3.49K
INSM icon
70
CALL
Insmed
INSM
$21.4B
– –
-20,500
Closed -$128K
INSM icon
71
Insmed
INSM
$21.4B
– –
-15,400
Closed -$597K
IOVA icon
72
PUT
Iovance Biotherapeutics
IOVA
$1.82B
– –
-15,500
Closed -$25.9K
KORE
73
DELISTED
KORE Group Holdings
KORE
– –
-9,420
Closed -$37.1K
NOTV
74
DELISTED
Inotiv
NOTV
– –
-13,561
Closed -$148K
NVO
75
Novo Nordisk
NVO
$208B
– –
-3,000
Closed -$385K
1 2
3
4

Similar funds

VL
Vorpal LLC Nashville, Tennessee $32M AUM 10.89% 1-Year Est. Return
SP
SCF Partners Houston, Texas $32.2M AUM 191.71% 1-Year Est. Return
OGC
One68 Global Capital New York $30.9M AUM
PE
Platinum Equity Beverly Hills, California $32.3M AUM 17.64% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
LGM
Lykos Global Management Stamford, Connecticut $30.4M AUM
SCA
SMH Capital Advisors Fort Worth, Texas $32.9M AUM 1.53% 1-Year Est. Return

Worth Venture Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Worth Venture Partners held 84 positions worth $13.5M, down 10% from $15M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Worth Venture Partners deployed $17.1M of net new capital in Q2 2024, opening 22 new positions and adding to 18 existing holdings. Its largest new stake was Pfizer: 29,100 shares worth $814K.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 30% a quarter earlier, followed by Real Estate and Technology.

On the sell side, the largest reduction was Innovid Corp., an estimated $64.2K trimmed.

  • Worth Venture Partners's largest Q2 2024 buy was Pfizer: 29,100 shares worth $814K.
  • Worth Venture Partners added most to Weave Communications in Q2 2024, an estimated $715K increase.
  • Worth Venture Partners's biggest Q2 2024 reduction was Innovid Corp., cutting an estimated $64.2K.
  • Worth Venture Partners fully exited Arteris in Q2 2024, selling an estimated $1.01M.
  • Worth Venture Partners's ten largest holdings make up 55% of its $13.5M portfolio in Q2 2024.
  • Worth Venture Partners opened 22 new positions and closed 28 in Q2 2024.
  • Worth Venture Partners's portfolio value fell 10% quarter-over-quarter to $13.5M.

Based on Worth Venture Partners's 13F filing for Q2 2024, filed 14 Aug 2024.